Tamer M Hadi, MD
Ophthalmology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 33
- 10 carriers
- Offices
- 2
Offices
2 locations · Bdhv Medical Group of California PC · Permanente Medical Group Inc
Looking this up.
Hospitals listed: Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
33 plans · 10 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hadi’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
33 of 33 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A156074 · Current
Licensed to practise in California · since 2018 · expires 2028-03-31 · Virginia Commonwealth University, Medical College of Virginia.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$272,153
Medicare paid this office $272,153 for 399 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 25 | $79,495 | None |
| Established patient complete exam of visual system | 323 | $68,997 | $120 |
| Imaging of retina | 333 | $23,244 | $38 |
| Injection of drug into eye | 45 | $14,612 | $115 |
| Return visit (30+ min) | 86 | $5,796 | $64 |
See all 10 services
| Injection, aflibercept, 1 mg | 25 | $79,495 | None |
| Established patient complete exam of visual system | 323 | $68,997 | $120 |
| Imaging of retina | 333 | $23,244 | $38 |
| Injection of drug into eye | 45 | $14,612 | $115 |
| Return visit (30+ min) | 86 | $5,796 | $64 |
| Photography of the retina | 74 | $3,230 | $35 |
| Injection, bevacizumab, 10 mg | 18 | $2,416 | None |
| Short return visit (20+ min) | 27 | $1,861 | $64 |
| New patient complete exam of visual system | 11 | $1,512 | $137 |
| Imaging of optic nerve | 34 | $960 | $26 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
399 Original Medicare patients in 2024. Average age 78 · Under 65 3% · 85 and older 23% · Women 63% · Also on Medicaid 14% · Health risk score 1.24. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 35% · Coronary heart disease 27% · Chronic kidney disease 23% · Cancer 18% · Depression 18% · Atrial fibrillation 17% · Heart failure 13% · COPD 12% · Stroke 11% · Dementia 6%.
The office billed $739,031, Medicare allowed $362,108 and paid $272,153; for 2,861 services of 35 kinds; $126,993 of it was for drugs given in the office and $145,159 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 399 | 2,861 | 78 | 1.24 | $739,031 | $272,153 |
| 2023 | 558 | 3,602 | 77 | 1.19 | $859,516 | $308,746 |
| 2022 | 655 | 2,717 | 77 | 1.15 | $760,947 | $271,932 |
| 2021 | 576 | 2,343 | 78 | 1.14 | $738,292 | $254,897 |
| 2020 | 222 | 614 | 77 | 1.30 | $203,891 | $61,985 |
| 2019 | 76 | 116 | 71 | 1.80 | $160,358 | $11,838 |
| 2018 | 31 | 42 | 76 | 1.80 | $31,447 | $2,225 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Injection, aflibercept, 1 mg | 24 | $81,778 | None |
| Return visit (30+ min) | 387 | $81,341 | $111 |
| Imaging of retina | 428 | $28,425 | $38 |
| Injection of drug into eye | 41 | $14,321 | $111 |
| Established patient complete exam of visual system | 126 | $13,890 | $101 |
| Short return visit (20+ min) | 85 | $7,338 | $72 |
| Photography of the retina | 120 | $5,551 | $34 |
| New patient complete exam of visual system | 51 | $5,042 | $99 |
| New patient visit (45+ min) | 28 | $4,159 | $149 |
| Imaging of optic nerve | 93 | $3,795 | $32 |
| Exam of visual field with extended testing | 42 | $3,004 | $64 |
| Injection, bevacizumab, 10 mg | 21 | $2,205 | None |
| 2d ultrasound scan of eye tissue and structures | 12 | $754 | $25 |
| Ct scan of cornea | 13 | $453 | $35 |
| Ultrasound scan of cornea to determine thickness | 14 | $134 | $10 |
2022: 16 services
| Injection, aflibercept, 1 mg | 18 | $70,996 | None |
| Return visit (30+ min) | 336 | $66,722 | $110 |
| Imaging of retina | 478 | $29,192 | $37 |
| Established patient complete exam of visual system | 248 | $25,855 | $103 |
| Short return visit (20+ min) | 156 | $17,520 | $77 |
| Injection of drug into eye | 30 | $8,467 | $114 |
| New patient complete exam of visual system | 70 | $7,826 | $112 |
| Exam of visual field with extended testing | 63 | $4,230 | $60 |
| Photography of the retina | 91 | $3,991 | $35 |
| Imaging of optic nerve | 93 | $3,879 | $33 |
| New patient visit (45+ min) | 25 | $3,618 | $145 |
| Short return visit | 28 | $1,564 | $54 |
| Injection, bevacizumab, 10 mg | 13 | $1,259 | None |
| Ct scan of cornea | 24 | $810 | $32 |
| 2d ultrasound scan of eye tissue and structures | 11 | $489 | $41 |
| Ultrasound scan of cornea to determine thickness | 20 | $184 | $9 |
2021: 17 services
| Injection, aflibercept, 1 mg | 15 | $59,696 | None |
| Return visit (30+ min) | 270 | $46,904 | $114 |
| Established patient complete exam of visual system | 239 | $29,422 | $117 |
| Imaging of retina | 433 | $25,783 | $40 |
| Short return visit (20+ min) | 152 | $16,186 | $85 |
| Removal of cataract with insertion of prosthetic lens | 23 | $16,133 | $538 |
| New patient complete exam of visual system | 87 | $10,837 | $125 |
| Injection of drug into eye | 21 | $6,685 | $115 |
| Exam of visual field with extended testing | 76 | $5,853 | $63 |
| Removal of recurring cataract in lens capsule using a laser | 11 | $4,158 | $320 |
| Photography of the retina | 85 | $3,994 | $40 |
| Imaging of optic nerve | 77 | $3,455 | $35 |
| Established patient problem focused exam of visual system | 29 | $2,669 | $92 |
| Measurement of corneal curvature and depth of eye | 40 | $2,502 | $57 |
| Ct scan of cornea | 46 | $1,853 | $35 |
| Short return visit | 15 | $905 | $57 |
| Ultrasound scan of cornea to determine thickness | 25 | $340 | $11 |
2020: 10 services
| Established patient complete exam of visual system | 98 | $12,476 | $126 |
| Return visit (30+ min) | 85 | $10,349 | $102 |
| Imaging of retina | 139 | $6,549 | $40 |
| New patient complete exam of visual system | 16 | $2,335 | $146 |
| Photography of the retina | 41 | $1,920 | $46 |
| Short return visit (20+ min) | 16 | $1,175 | $73 |
| Exam of visual field with extended testing | 16 | $1,054 | $66 |
| Imaging of optic nerve | 25 | $912 | $36 |
| Measurement of corneal curvature and depth of eye | 13 | $835 | $49 |
| Ct scan of cornea | 15 | $635 | $35 |
Medicaid work
$28,334 in 2024
Medicaid paid $28,334 for 357 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 66 | $16,777 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 223 | $8,075 |
| Short return visit | 34 | $2,646 |
| Return visit (30+ min) | 20 | $520 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 14 | $317 |
| 2024 | 357 | 5 | 21 | $28,334 |
| 2023 | 726 | 6 | 35 | $10,746 |
| 2022 | 82 | 2 | 15 | $1,054 |
| 2020 | 220 | 2 | 32 | $9,689 |
| 2019 | 197 | 2 | 30 | $9,469 |
| 2018 | 57 | 2 | 28 | $2,254 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 308 | $4,234 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 314 | $2,774 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 12 | $1,296 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 26 | $1,019 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 53 | $926 |
| New patient visit (45+ min) | 13 | $497 |
2022
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 68 | $889 |
| Return visit (30+ min) | 14 | $165 |
2020
| Return visit (30+ min) | 87 | $5,641 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 133 | $4,049 |
2019
| Return visit (30+ min) | 95 | $5,942 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 102 | $3,527 |
2018
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 43 | $1,532 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 14 | $722 |
Drugs they prescribed that Part D paid
$53,039
Pharmacies billed $53,039 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 486) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
335 generic and 151 brand-name prescriptions · $53,039 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rocklatan | 12 | $6,032 | $503 |
| Lumigan | 11 | $5,426 | $493 |
| Simbrinza | 14 | $2,718 | $194 |
| Latanoprost | 109 | $1,989 | $18 |
| Dorzolamide-Timolol | 69 | $1,070 | $16 |
See all 11 drugs
| Rocklatan | 12 | $6,032 | $503 |
| Lumigan | 11 | $5,426 | $493 |
| Simbrinza | 14 | $2,718 | $194 |
| Latanoprost | 109 | $1,989 | $18 |
| Dorzolamide-Timolol | 69 | $1,070 | $16 |
| Ketorolac Tromethamine | 43 | $1,061 | $25 |
| Brimonidine | 47 | $603 | $13 |
| Prednisolone Acetate | 17 | $517 | $30 |
| Timolol Maleate | 29 | $339 | $12 |
| Erythromycin | 33 | $314 | $10 |
| Diclofenac | 13 | $165 | $13 |
Year by year
| 2024 | 486 | 156 | 0% (0) | 31% | $53,039 |
| 2023 | 504 | 141 | 0% (0) | 48% | $51,352 |
| 2022 | 503 | 146 | 0% (0) | 42% | $45,069 |
| 2021 | 457 | 143 | 0% (0) | 53% | $38,758 |
| 2020 | 151 | 65 | 0% (0) | 37% | $23,959 |
| 2019 | 333 | 108 | None | 44% | $62,653 |
| 2018 | 126 | 64 | None | 40% | $20,009 |
| 2017 | 39 | 19 | 0% (0) | 49% | $2,214 |
| 2016 | 43 | 23 | None | 30% | $4,405 |
| 2015 | 62 | 27 | None | None | $5,883 |
| 2014 | 38 | 14 | None | None | $1,688 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Lumigan | 19 | $10,435 | $549 |
| Vyzulta | 14 | $7,120 | $509 |
| Rocklatan | 16 | $7,103 | $444 |
| Rhopressa | 17 | $6,380 | $375 |
| Latanoprost | 168 | $3,938 | $23 |
| Simbrinza | 16 | $3,149 | $197 |
| Dorzolamide-Timolol | 51 | $1,334 | $26 |
| Timolol Maleate | 37 | $595 | $16 |
| Brimonidine | 27 | $535 | $20 |
| Erythromycin | 50 | $486 | $10 |
| Neomycin-Polymyxin-Dexameth | 12 | $169 | $14 |
2022: 10 drugs
| Lumigan | 14 | $7,597 | $543 |
| Vyzulta | 14 | $7,360 | $526 |
| Latanoprost | 134 | $3,443 | $26 |
| Timolol Maleate | 25 | $1,202 | $48 |
| Dorzolamide-Timolol | 53 | $1,144 | $22 |
| Prednisolone Acetate | 26 | $971 | $37 |
| Erythromycin | 70 | $731 | $10 |
| Moxifloxacin | 16 | $517 | $32 |
| Brimonidine | 20 | $473 | $24 |
| Neomycin-Polymyxin-Dexameth | 18 | $225 | $13 |
2021: 9 drugs
| Prolensa | 19 | $5,914 | $311 |
| Prednisolone Acetate | 57 | $2,351 | $41 |
| Latanoprost | 73 | $2,183 | $30 |
| Brimonidine | 35 | $1,593 | $46 |
| Moxifloxacin | 46 | $1,315 | $29 |
| Erythromycin | 67 | $873 | $13 |
| Dorzolamide-Timolol | 25 | $664 | $27 |
| Neomycin-Polymyxin-Dexameth | 18 | $318 | $18 |
| Timolol Maleate | 19 | $229 | $12 |
2020: 2 drugs
| Latanoprost | 37 | $598 | $16 |
| Erythromycin | 14 | $199 | $14 |
2019: 10 drugs
| Restasis | 36 | $32,330 | $898 |
| Ilevro | 12 | $3,540 | $295 |
| Durezol | 14 | $2,650 | $189 |
| Dorzolamide-Timolol | 21 | $1,011 | $48 |
| Prednisolone Acetate | 21 | $840 | $40 |
| Latanoprost | 50 | $777 | $16 |
| Brimonidine | 18 | $661 | $37 |
| Ketorolac Tromethamine | 25 | $443 | $18 |
| Diclofenac | 17 | $244 | $14 |
| Timolol Maleate | 20 | $127 | $6 |
2018: 3 drugs
| Restasis | 11 | $9,418 | $856 |
| Prednisolone Acetate | 17 | $848 | $50 |
| Latanoprost | 18 | $253 | $14 |
2017: 1 drug
| Prednisolone Acetate | 12 | $814 | $68 |
Money from drug and device companies
$48 in 2025
| 2025 | 1 | 2 | None | $48 |
| 2024 | 3 | 3 | None | $68 |
| 2023 | 6 | 10 | None | $379 |
| 2022 | 13 | 25 | None | $573 |
| 2021 | 10 | 26 | None | $499 |
| 2020 | 7 | 12 | None | $446 |
| 2019 | 4 | 10 | None | $2,145 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tepezza | $48 | 2 payments
|
See all 2 published payments
| Amgen | Meals · 2025-08-18 | Tepezza | $23 |
| Amgen | Meals · 2025-04-09 | Tepezza | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $68
| Alcon Vision | Rocklatan | $24 | 1 payment
|
| Amgen | Tepezza | $23 | 1 payment
|
| Sight Sciences | Omni Surgical System | $21 | 1 payment
|
2023: $379
| Alcon Vision | Rocklatan | $179 | 3 payments
|
| Apellis Pharmaceuticals | Syfovre | $67 | 2 payments
|
| Astellas Pharma US | None | $60 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $27 | 1 payment
|
| Biotissue Holdings | Prokera | $23 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $23 | 1 payment
|
2022: $573
| Apellis Pharmaceuticals | None | $124 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $123 | 8 payments
|
| Alcon Vision | Rhopressa | $43 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $41 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $39 | 2 payments
|
| Kala Pharmaceuticals | Inveltys | $38 | 2 payments
|
| Bausch & Lomb Americas | Vyzulta | $36 | 2 payments
|
| Glaukos | Istent Inject W | $24 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $23 | 1 payment
|
| Abbvie | Vuity | $23 | 1 payment
|
| Allergan | Vuity | $22 | 1 payment
|
| Genentech USA | Vabysmo | $21 | 1 payment
|
| BioTissue Holdings | Prokera | $18 | 1 payment
|
2021: $499
| Mallinckrodt Hospital Products | Acthar | $212 | 9 payments
|
| Kala Pharmaceuticals | Inveltys | $52 | 3 payments
|
| Novartis Pharmaceuticals | Xiidra | $40 | 2 payments
|
| Allergan | Durysta | $38 | 3 payments
|
| Sun Pharmaceutical Industries | Cequa | $36 | 2 payments
|
| Tissuetech | Prokera | $34 | 2 payments
|
| Aerie Pharmaceuticals | Rocklatan | $31 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Infuse | $23 | 1 payment
|
| TearLab | Tearlab Osmolarity System | $19 | 1 payment
|
| Dompe US | Oxervate | $14 | 1 payment
|
2020: $446
| Regeneron Healthcare Solutions | Eylea | $123 | 1 payment
|
| Allergan | Ozurdex | $111 | 1 payment
|
| Aerie Pharmaceuticals | Rhopressa | $63 | 3 payments
|
| Sun Pharmaceutical Industries | Xelpros | $53 | 3 payments
|
| Bausch & Lomb a division of Bausch Health US | Lotemax Sm | $48 | 2 payments
|
| Glaukos | Istent Inject Trabecular Micro-Bypass Stent System | $29 | 1 payment
|
| Optos | P200dtx | $19 | 1 payment
|
2019: $2,145
| Regeneron Pharmaceuticals | None | $1,541 | 5 payments
|
| Novartis Pharmaceuticals | None | $304 | 3 payments
|
| Dutch Ophthalmic USA | Eva Ophthalmic Surgical System | $173 | 1 payment
|
| Allergan | Ozurdex | $127 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 92.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407274913
- Licence
- CA A156074California A156074: Current · expires 2028-03-31
- Trained
- Virginia Commonwealth University, School of Medicine, 2014
- Group
- Bdhv Medical Group of California PC · Permanente Medical Group Inc
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0107X (207WX0107X); Student in a training program (390200000X)
- Mailing address
- 220 Meridian Ave, San Jose, CA, 95126
- NPI first listed
- 2014-04-01
- NPI last updated
- 2023-03-07
- NPI record certified
- 2020-10-13
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.